Lyell Immunopharma, Inc. announced its financial results for Q4 and the full year 2025, reporting a net loss of $140.7 million for Q4 and $274.4 million for the year. The company has commenced patient dosing in pivotal trials and closed a $50 million equity placement.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.